Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414607 · ClinicalTrials.gov registry record · Phase 1
Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment
A Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02414607 is a Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 24 participants.
The verdict
NCT02414607, a Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Elderberries (Sambuci fructus) have been shown in a number of studies to have significant anti-inflammatory and antioxidant effects. Multiple human and animal studies have supported the anti-inflammatory and antioxidant effects of elderberry preparations and it has been used in natural medicine for hundreds of years. Studies examining factors that may decrease the risk of Alzheimer's disease have revealed that drinking juices with similar properties to elderberries is one of the most reliable way to decrease risk. As such the investigators wish to determine the effects of elderberry juice on cognitive decline in a group of subjects at high risk for Alzheimer's disease, those with mild cognitive impairment. Elderberry juice is a commercially available nutritional supplement and easily available to this population.
Interventions
- OTHER Placebo
- BIOLOGICAL Elderberry Juice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02414607
The ClinicalTrials.gov registry entry for NCT02414607 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02414607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02414607 about?
NCT02414607 is a clinical study titled "Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment". Elderberries (Sambuci fructus) have been shown in a number of studies to have significant anti-inflammatory and antioxidant effects. Multiple human and animal studies have supported the anti-inflammatory and antioxidant effects of elderberry preparations and it has been used in natural medicine for ...
What is the current status of trial NCT02414607?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-09. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02414607?
The interventions under investigation include: Placebo (OTHER), Elderberry Juice (BIOLOGICAL).
Who is sponsoring clinical trial NCT02414607?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.